You are here

Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.

SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place November 4-7, 2018 in Washington D.C. The presentations will focus on recently completed studies demonstrating pharmacokinetics and tolerability of DARE-HRT1, a novel 17β- estradiol and progesterone intravaginal ring being developed for the treatment of vasomotor symptoms (VMS) commonly associated with the onset of menopause, and DARE-FRT1, a novel progesterone intravaginal ring (IVR) being developed for potential utilization in both in-vitro fertilization (IVF) and pre-term birth.

“The compelling preclinical results demonstrate the ability to achieve target pharmacokinetic and tolerability objectives for both a single active IVR (DARE-FRT1) and dual active IVR  (DARE-HRT1),” said Dr. David Friend, Daré’s Chief Scientific Officer. “We believe that the capabilities of the IVR technology will expand our ability to identify and meet unmet needs in women’s sexual and reproductive health, and we look forward to advancing the technology into human clinical studies.”

The current 505(b)(2) candidates under development, DARE-HRT1 and DARE-FRT1, formerly JNP-0201 and JNP-0301 respectively, were licensed by Daré from Juniper Pharmaceuticals in a transaction announced on April 25, 2018, as was the candidate DARE-OAB1, formerly JNP-0101. The IVR technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and by Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School. Daré’s exclusive license covers the rings in development as well as additional applications of the IVR technology platform in other therapeutic areas.

This IVR technology allows for active drug to be homogenized in a solid EVA polymer matrix and eliminates the need for a membrane or reservoir to contain the active drug or control the release.  Individual drug segments provide the opportunity for multiple drug and dosage level options.  Compared to other drug delivery vehicles, these features provide flexibility to incorporate a wide molecular weight range including poorly bioavailable drugs.

The abstracts will be presented in a poster session by Daré’s Chief Scientific Officer, David Friend, Ph.D.

Poster Abstract Presentation Details for DARE-HRT1
Date: Tuesday, November 6, 2018
Time: 11:30 AM – 2:00 PM
Publication: T1130--12-095
Presentation Type: Poster
Title: Pharmacokinetic and tolerability study of a novel 17β-estradiol and progesterone intravaginal ring in sheep

Poster Abstract Presentation Details for DARE-FRT1
Date: Wednesday, November 7, 2018
Time: 9:30 AM – 2:00 PM
Publication: W0930--09-72
Presentation Type: Poster
Title: Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep 

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring, and Sildenafil Cream, 3.6%, a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to the capabilities of the IVR technology to expand Daré’s ability to identify and meet unmet needs in women’s sexual and reproductive health, and to Daré’s ability to advance the technology into human clinical studies. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, and other factors discussed in the "Risk Factors" section of Daré's Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2018. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré's reports to the Securities and Exchange Commission, including Daré's reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.


Investors on behalf of Daré Bioscience, Inc.:
Ami Bavishi
Burns McClellan


Media on behalf of Daré Bioscience, Inc.:
Amanda Guisbond
Canale Communications

Source: Daré Bioscience, Inc.

Tuesday, October 30, 2018 - 08:00